PRTG Portage Biotech Inc: Earnings per share for the last 12 months

Portage (PRTG) - corporate logo

Portage Biotech Inc. (PRTG) ensures operational continuity through the distribution of its production sites. The company relies on external contractors for drug development and testing. A broad pipeline of researched molecules reduces overall risks. On GURU.Markets, the annual EPS growth based on financial statements (TTM) demonstrates profit dynamics, where -545.70 represents the latest level value.

Portage (PRTG) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

PRTG (Portage Biotech Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
- company stock capitalization data:
Fundamental company valuation:PRTG Portage
Flagship merchandise of Portage Biotech

EPS TTM growth measures the trailing twelve-month net income per share, reflecting the actual quality of generated revenue. By analyzing the current annual EPS TTM growth rate, an investor can gauge the efficiency of intellectual property monetization. For Portage Biotech Inc. (PRTG), this metric correlates with immuno-oncology screening rates and adherence to contract manufacturing schedules. A stable trajectory confirms the business model's resilience to external shocks, while a positive trend signals a transition from cost-intensive research to asset capitalization.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months nucana.com|CMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CYCC|Net earnings per share (EPS TTM) G1 Therapeutics Inc. (GTHX)|Earnings per share for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Earnings per one share for the last 12 months|ONCT: Net earnings per share for the last 12 months